趋化因子受体CXCR2及其配基GROα、IL-8与肿瘤关系的研究进展

Research advances of relationship between chemokine receptor CXCR2 and its ligands GROα and IL-8 in cancer

CXCR2是趋化因子受体家族中的重要一员,近年来研究发现CXCR2及其主要配体生长调节性癌基因-α(growth-regulated oncogene-α,GROα)和白介素-8(IL-8)在肿瘤的发生发展过程中具有重要作用,不仅可以促进肿瘤的发生和形成,而且可以通过增加肿瘤的血管生成促进肿瘤的生长、浸润和转移。CXCR2及配体还可作为肿瘤标志物和独立预后因子用于肿瘤的早期诊断和预后判断。目前,抗CXCR2的各类药物正在进行各种基础和临床试验研究,因此作为新的靶向分子有望成为特异性药物作用靶点,从而为肿瘤分子靶向治疗开辟新途径。

CXCR2 is an important member of chemokine receptor family. Recently, more and more studies have revealed that CXCR2 and its major ligands GROα and IL-8, play an important role in the development and advancement of tumor. They not only promote tumorigenesis, but also contribute to tumor growth, infiltration, and metastasis through tumor angiogenesis. CXCR2 and the ligands can be used as tumor markers and independent prognostic factors to predict early diagnosis and prognosis. Moreover, CXCR2 is hopeful to be specific drug target, and to provide a new approach for molecule-targeted therapy.